Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Wuxi Biologics Cayman Inc ADR
(OP:
WXXWY
)
9.320
-0.090 (-0.96%)
Streaming Delayed Price
Updated: 3:53 PM EDT, Oct 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
21,292
Open
9.310
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
9.410
Today's Range
9.225 - 9.400
52wk Range
3.600 - 11.21
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Trump Reportedly Warns Big Pharma: Move Manufacturing To US Or Face Tariffs
February 24, 2025
President Donald Trump has issued a stringent warning to pharmaceutical companies, advising them to repatriate their manufacturing to the US or face the possibility of tariffs.
Via
Benzinga
Topics
Government
Week In Review: Curon Out-Licenses T-Cell-Engager To Merck For $700 Million Upfront
August 10, 2024
Curon Biopharmaceutical, a Shanghai company, out-licensed global rights for a clinical-stage bispecific candidate to Merck (MSD) for $700 million upfront plus $600 million in milestones.
Via
Talk Markets
Performance
YTD
+117.8%
+117.8%
1 Month
-6.7%
-6.7%
3 Month
+27.7%
+27.7%
6 Month
+82.0%
+82.0%
1 Year
+143.5%
+143.5%
More News
Read More
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
March 23, 2024
Via
Talk Markets
Congressional Scrutiny Intensifies On Chinese Biotech Firms: WuXi AppTec Faces Biotech Exodus
March 14, 2024
Via
Benzinga
Week In Review: BeiGene Options DualityBio ADC In $1.3 Billion Agreement
July 15, 2023
Via
Talk Markets
Week In Review: BeiGene Signs $1.3 Billion Deal For Preclinical CDK2 Inhibitor From Boston’s Ensem
November 25, 2023
Via
Talk Markets
Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal
November 18, 2023
Via
Talk Markets
Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion Deal
November 11, 2023
Via
Talk Markets
Strong Consumer Turnout Drives Hong Kong Stocks Higher Friday As China's Former Premier Li Keqiang Dies At 68
October 27, 2023
Via
Benzinga
Week In Review: China's Biopharmas Announce $2.5 Billion In Deals
October 21, 2023
Via
Talk Markets
Week In Review: QYuns Plans Hong Kong IPO For Autoimmune/Allergic Disease Portfolio
October 07, 2023
Via
Talk Markets
Topics
Initial Public Offering
Week In Review: WuXi Biologics Out-Licenses Four TCE Antibodies To GSK In $1.5 Billion Pact
January 07, 2023
Via
Talk Markets
Week In Review: Ten Biggest 2022 China Biopharma Deals Worth $21.5 Billion
December 31, 2022
Via
Talk Markets
Wuxi Biologics Will Be Removed From U.S. Commerce Department's ‘Unverified List’
October 09, 2022
Via
Talk Markets
Frequently Asked Questions
Is Wuxi Biologics Cayman Inc ADR publicly traded?
Yes, Wuxi Biologics Cayman Inc ADR is publicly traded.
What exchange does Wuxi Biologics Cayman Inc ADR trade on?
Wuxi Biologics Cayman Inc ADR trades on the OTC Traded
What is the ticker symbol for Wuxi Biologics Cayman Inc ADR?
The ticker symbol for Wuxi Biologics Cayman Inc ADR is WXXWY on the OTC Traded
What is the current price of Wuxi Biologics Cayman Inc ADR?
The current price of Wuxi Biologics Cayman Inc ADR is 9.320
When was Wuxi Biologics Cayman Inc ADR last traded?
The last trade of Wuxi Biologics Cayman Inc ADR was at 10/17/25 03:53 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.